UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 27, 2006
Cholestech Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
California
|
|
000-20198
|
|
94-3065493 |
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.) |
3347 Investment Boulevard
Hayward, California 94545
(Address of principal executive offices, including zip code)
(510) 732-7200
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 2.02 Results of Operations and Financial Condition
On July 27, 2006, Cholestech Corporation (Cholestech) is issuing a press release and holding
a conference call regarding its financial results for the first quarter ended June 30, 2006. A
copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated by reference.
The information in this Current Report on Form 8-K and the exhibit attached hereto shall not
be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange
Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any
general incorporation language in such filing.
Use of Non-GAAP Financial Measures
To supplement our results presented in accordance with generally accepted accounting
principles (GAAP), we use non-GAAP measures of operating results, net income and net income per
share, which are adjusted from results based on GAAP to exclude SFAS
123R stock-based compensation
expenses. This non-GAAP financial presentation is given in part to enhance the understanding of the
Companys historical financial performance and comparability between periods in light of a change
in accounting standards, particularly since the Company has not included stock-based compensation
under SFAS 123R as an expense in financial statements before. In addition, the Company believes
that the non-GAAP presentation to exclude stock-based compensation is relevant and useful
information that will be widely used by analysts, investors and other interested parties. Cash
earnings is not a GAAP defined measure. The company believes this measure provides meaningful
supplemental information regarding Cholestechs operating results given the current accumulated tax
loss carryforwards and because it excludes amounts that are not related to Cholestechs core
operating results and facilitate the comparison of results for the current period with results for
past periods. Further, these non-GAAP results are one of the primary indicators management uses
for assessing our performance, allocating resources and planning and forecasting future periods.
Accordingly, the Company is disclosing this information to permit additional analysis of the
Companys performance. These measures should be considered in addition to results prepared in
accordance with GAAP, but should not be considered a substitute for or superior to GAAP results.
Item 9.01. Financial Statements and Exhibits
(c) Exhibits
|
|
|
Exhibit No. |
|
Description |
|
|
|
99.1
|
|
Press Release of Cholestech Corporation dated July 27, 2006 |
2